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For the first time, microRNA was discovered by 
Lee et al. in 1993 (1). MiRNAs play both as 
oncogenes as well as tumor suppressive (2,3). 
Therefore, recognizing miRNAs as the important 
factors in induction and suppression of tumor effects  
is shown to be very important (4-6).  
One of the treatment strategies is chemotherapy 
which is widely used in the treatment of cancer 
patients. In one hand, chemoresistance is one of the 
major problems of these treatment strategies (7,8). 
Therapeutic options due to different molecular 
mechanisms and early diagnosis enter in a challenge  
MiRNAs play an important role as oncogenes and tumor 
suppressors in induction and suppression of tumor effects. 
Also in different stages of cancer therapy. High and low 
expression of some miRNAs could be used as factors for 
prognosis patients drug resistant. Regulation of these 
miRNA perform by some other miRNA that can 
suppression or active the translation of downstream 
miRNA, therefore, miRNAs play important role in the 
individual treatments and classification of miRNA in 
diagnosis and prognosis is highly valuable, also we could 
consider miRNA as a setting key for switching and off of 
genes. 
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with chemoresistance in patients with breast, 
glioblastoma, prostate cancer. Therefore, about30% 
of patients with breast cancer are faced to relapse 
with metastasis in the event of drug resistance (9-
11). Chemotherapies, including taxanes and 
anthracyclines, may response up over 70% at the 
early stages of the disease but can drop to 20 to 30% 
after progression of the disease (8,12). Therefore, in 
addition to the mal-effects of metastasis, 
chemoresistance  ،a major obstacle for the treatment 
of cancer. As a result, by the elimination of drug 
resistance, better clinical systems can be provided 
for patients with other cancer. 
 
Literature review  
Despite the fact that miRNAs do not code any 
protein and their loci are located in non-coding 
regions of intronic transcription, but they have rarely 
been observed in the exonic region, too (13,14). 
miRNA genes in the cell nucleus are transcribed by 
RNA polymerase II enzyme so that a pri-miRNA 
(primary miRNA) is produced which is finally 
converted to a pre-miRNA by the set of the drosha-
DGCR8 complex. Exportin 5 binds to pre-micro 
RNA hairpins (pre-miRNA hairpins) and transfers to 
the cytoplasm and in the cytoplasm, it will be 
subjected to some important changes by RNaseIII-
type enzyme dicer. The pre-miRNA, two single 
stranded miRNAs are produced with the names: (a) 
miRNA-3p and (b) miRNA-5p (13). Previously, it 
was commonly believed that a mature miRNA is 
single-stranded and the other strand of it is called the 
passenger strand which finally, will be decomposed, 
whereas, the current theory states that each strand 
acts as a mature miRNA (15,16). This phenomenon 
is clearly seen in cancer and about 300 human 
patients (17-20). in addition, significantly affects the 
results of drug specifications. For example, highly 
expressed miR-34a in breast cancer cells line is 
directly related to resistance to docetaxel drug, 
whereas, in quite opposite from, high expression of 
miR-34a leads to the sensitivity of Ewing's sarcoma 
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cells to doxorubicin and vincristine drug (21,22). 
Various anticancer drugs, through the activation of 
intrinsic and extrinsic pathways, cause to induce the 
apoptosis in the tumor cells (23). Two main 
mechanisms lead apoptosis: the mitochondrial 
intrinsic pathway and the transmembrane extrinsic 
pathway. The main strategy is to control the Bcl-2 
family which includes more than 30 molecules 
regulating apoptosis (24). Some of miRNAs in 
partnership with Bcl-2 family are involved in 
cellular apoptosis. For example, miRNA-15/16, miR
-21.  MiR-125b in partnership with Bcl-2 act as an 
anti-apoptosis factor. In most tumors, when miR-21 
is connected to the miRNA (3'-UTR) of BCL2, it 
shows the apoptotic functions (25). The relationship 
between miRNAs and cancer stem cell identifying 
several miRNAs as the key to controlling the 
glioblastoma, prostate cancer, and breast cancer was 
introduced (26). 
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Conclusion 
When the effects of miRNAs in drug resistance may be positive or negative, so we can classify them both as 
useful and harmful. To understand the role of miRNAs in human cancer, including different settings of 
miRNA on their goals as well as the key role in the formation of apoptotic process can be very promising in 
the therapeutic section. Due to the medical science becoming molecular, miRNAs play an important role in 
the individual treatments of and classification of miRNAs in diagnosis and prognosis is highly valuable. 
Therefore, by understanding the developing role and importance as well as the practical potentials of miRNA 
it's necessary that the young researchers of our country focus further on researching in this area of genetics. 
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